Assessment Publication: Jointly Produced HTA Report; Partner Profile: Austria; Impact: Austria; Partner Profile: UK; Innovation & HTA: Giovanni Tafuri; Prioritisation List: Topics & Joint Assessments; 2018: Year in Review Download your copy HERE.
EUnetHTA recently started a new Joint Assessment on a medicinal product for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response with. lost response to, or were intolerant to either
EUnetHTA recently started a new Joint Assessment on a medicinal product for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for hematopoietic stem cell transplant. To find out more about how patient
EUnetHTA publishes the EUnetHTA Prioritisation List (EPL) Find the EPL HERE The EPL expresses the identified significant interest of national HTA bodies in relation to individual compounds as presented in the list. By pro-actively selecting those topics in direct collaboration with national
HTA proposal: update; HTA reports; Impact: Italy; Interview: EP Rapporteur: Soledad Cabezón Ruiz MEP; Partner Profile: AIFA; Senior Science Officer: Giovanni Tafuri; working together: HTA Network Stakeholder Pool Downloadable PDF HERE [pdf-embedder url="https://www.eunethta.eu/wp-content/uploads/2018/10/Fall_2018_Magazine-2.pdf" title="Fall_2018_Magazine (2)"]
"HTA cooperation produces and will produce very tangible benefits not only for patients, but also improve the quality and sustainability of health systems when Europe needs them most." [vc_row][vc_column][vc_single_image image="15600" img_size="large"][vc_column_text] [pdf-embedder url="https://www.eunethta.eu/wp-content/uploads/2018/09/Summer_2018_Magazine-2-Photos-Sidebar-and-1-Column.pdf" title="Summer_2018_Magazine - 2 Photos, Sidebar, and 1 Column"][/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][/vc_column][/vc_row]
EUnetHTA Magazine – Summer 2018 HERE HTA Proposal: Is It Lights Out?; HTA reports; Impact: Lithuania; Interview: EURORDIS; Partner Profile: Poland; Non-Duplication: What’s in it for us? [pdf-embedder url="https://www.eunethta.eu/wp-content/uploads/2018/09/summer_2018_magazine_digital_FINAL-1.pdf" title="summer_2018_magazine_digital_FINAL"]
OTCA16 Bioresorbable Stents in cardiovascular indications (coronary artery disease) Project Plan Now Available
The final project plan of the assessment on “Bioresorbable Stents in cardiovascular indications (coronary artery disease)” and the comments provided by the external experts and the manufacturers are now available. OTCA16 Project Plan HERE OTCA16 External Expert and Manufacturer Comments HERE
The Joint Assessment, OTJA08, on “Continuous glucose monitoring (CGM real-time) and flash glucose monitoring (FGM) as personal, standalone systems in patients with diabetes mellitus treated with insulin” is now available.
We are pleased to announce that the joint rapid assessment on “Continuous glucose monitoring (CGM real-time) and flash glucose monitoring (FGM) as personal, standalone systems in patients with diabetes mellitus treated with insulin” is available. The health technologies assessed include rtCGM